Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GIST under imatinib therapy.

Seminars in diagnostic pathology - 1 May 2006

Sciot Raf, Debiec-Rychter Maria

Abstract excerpt

The prognosis of patients with a GIST improved significantly since the introduction of imatinib mesylate treatment, leading to disease control in 70% to 85% of patients. The response depends on the presence/ absence and type of mutations in the KIT or Platelet derived growth factor receptor. Unfortunately, we are increasingly faced with the problem of resistance to imatinib treatment, mainly secondary resistance,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leiomyosarcoma

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 17193821
DOI: 10.1053/j.semdp.2006.08.005

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GIST under imatinib therapy.PMID 17193821Read ↗

[GIST refractory to imatinib treatment].Semantic proximity Read ↗

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.Semantic proximity Read ↗

Gastrointestinal stromal tumor: a bridge between bench and bedside.Semantic proximity Read ↗

[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].Semantic proximity Read ↗

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.Semantic proximity Read ↗

[The importance of mutational status in prognosis and therapy of GIST].Semantic proximity Read ↗

GISTogram: a graphic presentation of the growing GIST complexity.Semantic proximity Read ↗

KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.Semantic proximity Read ↗

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.Semantic proximity Read ↗

Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review).Semantic proximity Read ↗

Gastrointestinal stromal tumors: who should get imatinib and for how long?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.